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Abstract
Introduction: We  escribe a simplified distributional cost effectiveness analysis based on aggregate 
data to estimate the health inequality impact of public health interventions.  
Methods: We extracted data on costs, health outcomes expressed as quality adjusted life years 
(QALYs), and target populations, for interventions within NICE public health guidance published up 
to October 2016.  Evidence on variation by age, sex and index of multiple deprivation informed 
socioeconomic distributions of incremental QALYs, health opportunity costs, and the baseline 
distribution of health.  Total population QALYs, summary measures of inequality and a health equity 
impact plane show results by intervention, and by guideline.  A value for inequality aversion from a 
general population survey in England let us combine impacts on health inequality and total health into 
a single measure of intervention value.  
Results: Our estimates suggest that of 134 interventions considered by NICE: 70 (52%) reduce 
inequality and increase health; 21 (16%) involve a trade-off between improving health and improving 
health inequality; and 43 (32%) reduce health and increase health inequality.  Fully implemented, the 
potential impact of all recommendations was 23,336,181 additional QALYs for the population of 
England and Wales, and a reduction of the gap in quality adjusted life expectancy between the 
healthiest and least healthy from 13.78 to 13.34 QALYs.  The combined value of the additional health 
and reduction in inequality was 28,723,776 QALYs.
Discussion: Our analysis takes account of the fact that existing public health spending likely benefit 
the most disadvantaged.  This simple method applied separately to economic evaluation produces 
evidence of intervention impacts on the distribution of health that is vital in determining value for 
money when health inequality reduction is a policy goal.
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Introduction
In the UK, no formal approach prescribes how health inequality impacts should inform public health 
investment decisions.  In England women and men in the most deprived areas live up to 9 years 
fewer, and have up to 20 fewer years in good health, compared to those in the least deprived areas.(1)  
The reduction of health inequalities associated with socioeconomic factors is a prominent social goal, 
demonstrating that societies regard these inequalities as unfair and value lessening of inequalities 
alongside improving health.(2, 3)  It has been argued that public health interventions can tackle this 
objective through their focus on lifestyle changes and other social determinants of health.(4, 5)   
The National Institute for Health and Care Excellence (NICE) produces public health guidelines that 
recommend interventions for provision by national and local healthcare commissioners, or within the 
wider public and private sectors.  NICEs equality objectives note that public health guidance in 
particular is concerned with tackling health inequalities associated with underlying socioeconomic 
factors and with inequities in access for certain disadvantaged groups.(6)  The current guidance does 
not describe a process by which Public Health Advisory Committees (PHACs) should take account  of 
impact on health inequalities in their recommendations.  A formal review of the available evidence 
supported with expert testimony and economic evaluation informs their recommendations.  The 
economic evaluations estimate the scale of the health benefits produced for a given investment in an 
intervention.  The PHAC make a judgement about whether the health benefits are valuable compared 
to alternative uses of the same resources.  However, the economic evaluations do not currently 
evaluate the distribution of outcomes within the population.  
Evidence on the health inequality impact of interventions presented to PHACs is typically qualitative 
and pertains to the characteristics of the target population. This informs the likely socioeconomic 
distribution of the benefits of the intervention, but fails to account for the distribution of the benefits 
produced by investing the intervention costs in other public health activities. This omission of 
opportunity cost prevents estimation of the magnitude of the inequality impact.  The socioeconomic 
distribution of health opportunity costs depends on the characteristics of individuals that benefit from 
existing services.  Where health inequalities are a policy concern, the magnitude of the net health 
inequality impact is relevant to determining value for money.  Producing recommendations without 
information on health inequality impacts risks failing to promote the most valuable interventions.  
In principle a formal distributional cost-effectiveness analysis could evaluate health inequality 
impacts to support each public health guideline.(7, 8)  In the absence of bespoke distributional 
analysis we demonstrate a method for conducting quantitative inequality impact assessment using 
available aggregate data.   We apply this to NICE guidelines conducted between 2006 and 2016 to 
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 timat  how the public health interventions considered affect the distribution of health, taking into 
account variation in health outcomes by age, gender and socioeconomic groups.  
Methods
The methods are based on distributional cost-effectiveness analysis, and we focus on change in 
lifetime health inequality across the whole population.(7)  Figure 1 shows the steps in combining 
information on additional costs and health outcomes produced by standard economic evaluation with 
routine data about the distribution of targeted health problems, and prior knowledge of health 
opportunity costs, according to age, gender, socioeconomic status.  In essence, this scales up average 
costs and health outcomes using patient population numbers, and disaggregates them to describe the 
distribution of health benefits by age, gender and socioeconomic status.  We show the calculations for 
public health guideline 43 (Hepatitis B and C testing) in Box 1.  Combining the distributions of 
intervention impacts with a baseline distribution of health shows how interventions and public health 
recommendations might affect lifetime health inequality in the English population.  We used quality 
adjusted life years (QALYs) and quality adjusted life expectancy (QALE) as our measure of health, 
and the Index of Multiple Deprivation (IMD) as our measure of socioeconomic status.(9)  
We describe seven stages of analysis: 
(i) Extract incremental costs and health benefits and size of the target population;
(ii) Estimate the distribution of population health benefits by gender and socioeconomic status;
(iii) Convert population costs into health opportunity costs;
(iv)  Estimate the distribution of population health opportunity cost by gender and socioeconomic 
status;
(v) Calculate the net health impact (health benefit minus health opportunity cost) for gender and 
socioeconomic subgroups;
(vi)  Combine net health impacts with a baseline distribution of lifetime health;
(vii) Calculate inequality measures on the pre- and post-intervention health distributions to 
summarise health inequality impact.
 
(i) Extract incremental costs and health benefits and size of the target population
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 viewed cost-effectiveness evidence and the associated PHAC recommendations for NICE 
public health guidance issued between March 2006 and October 2016. We extracted information from 
guidance documents, economic modelling reports and costing templates.  We excluded guidelines if: 
(i) no economic modelling was conducted; (ii) the economic modelling did not use QALYs as a health 
outcome measure; (iii) incremental costs and QALYs were not reported separately; (iv) hypothetical 
analyses were conducted rather than modelling specific interventions; (v) the guideline was obsolete. 
For each intervention we extracted the PHAC recommendation and the per recipient incremental costs 
and QALYs that formulated the base-case incremental cost-effectiveness ratios.  These represent the 
present value of the costs and QALYs accruing over the time horizon of the underlying cost-
effectiveness analysis, for which the NICE reference case indicates the use of an annual discount rate 
of 3.5%.  To estimate the number of recipients we extracted population size estimates from NICE 
documentation, and if unavailable, from alternative sources including previously published studies 
and national population statistics.  Where no specific intervention was explicit in PHAC 
recommendations, we used the Committee's consideration of the cost effectiveness evidence to inform 
assumptions about whether the intervention would fall under the general recommendation.  Where the 
economic evidence included a range rath r than a single estimate of cost-effectiveness for an 
intervention, we extracted the best and worst case, with the best case used for our primary analysis.
(ii) Estimate the distribution of population health benefits by gender and socioeconomic status 
We multiplied the target population size by the per person QALY gain to calculate the incremental 
population health benefit for each intervention.  This value represents the upper limit of health gains 
as it entails every person in the eligible population receiving the intervention (i.e. 100% reach and 
100% implementation) and does not account for any proportion of the population that may already be 
in receipt of the intervention.
To estimate the size of each gender and socioeconomic subgroup within a target population we first 
categorised interventions as: (i) targeting specific diseases, such as Type 2 diabetes; (ii) targeting 
health behaviours, such as smokers; or (iii) targeting disadvantaged groups such as low income or 
high deprivation populations.
For interventions targeting diseases, we mapped those diseases to three-digit International 
Classification of Disease (ICD) codes.  We then calculated subgroup sizes based on the corresponding 
proportion of NHS hospital activity by gender, IMD and ICD code for that group using Hospital 
Episode Statistics (HES) (2011-12 and 2012-13).  For interventions targeted by age, we used data 
from the relevant age band.  Where interventions targeted behaviours, we searched for data sources 
that reported behaviour distribution by gender and IMD.  For interventions specifically targeting low 
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ncome, disadvantaged or deprived groups we made a simplifying assumption that the health benefits 
would accrue to the most deprived fifth of the population in terms of IMD.  
(iii) Convert population costs into health opportunity costs
We calculated incremental population costs by multiplying the target population size by the per 
person incremental cost. As costs represent investments that could be spent elsewhere, namely other 
public health interventions, we converted them into health losses using an estimate of the health 
opportunity cost per pound of public sector expenditure. This value signifies the cost per QALY of 
services that could otherwise have been funded (or can be introduced if a public health intervention is 
cost saving).  We use a value of £20,000 per QALY for the base case analysis, which corresponds to 
the lower bound of the health sector cost-effectiveness threshold used within NICE.(10) If this figure 
is overestimated or if public health activities are more efficient than medical care activities this value 
underestimates health opportunity costs.(11-13)
(iv) Estimate the distribution of population health opportunity cost by gender and 
socioeconomic status
We found no published estimate of the socioeconomic gradient for marginal changes in public health 
expenditure, and so we assumed the same gradient as observed in NHS funded interventions.  The 
gender and socioeconomic distribution of population health gains from marginal changes in NHS 
expenditure has recently been estimated.(14)  We use this to represent the distribution of the health 
benefits that would have been produced by alternative public health interventions.  The distribution 
provides the proportion of the marginal QALY gain that would accrue to each gender and IMD 
subgroup, and when multiplied by the population health opportunity costs for each intervention this 
provides the subgroup health opportunity costs.
(v) Calculate the net health impact for gender and socioeconomic subgroups
The population net health impact by intervention and subgroup is the difference between the 
incremental population health benefits and incremental population health opportunity costs.  The 
impact by guideline is the sum of the costs and benefits of all interventions recommended within a 
guideline.  Where a guideline included recommendations for multiple interventions that would be 
mutually exclusive from an individual perspective we assumed an even split in utilisation across each 
intervention in the target population.
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(vi) Combine net health impacts with a baseline distribution of lifetime health
The baseline distribution of health represents existing health inequality by gender and socioeconomic 
status across the population in England and Wales.(15)  The incremental net health effects of each 
intervention or guideline added to this baseline provide a picture of health inequality following the 
implementation of the intervention or guideline.  This describes the impact of interventions at the 
level of the population of England and Wales.  
(vii) Calculate inequality impact measures
We chose the slope index of inequality (SII) and the relative index of inequality (RII) to summarise 
inequality in the distribution of health.(16)  The SII is commonly used in public health research when 
examining absolute inequality in life expectancy by IMD.  It is obtained by fitting an ordinary least 
squares model to estimate the slope or health gradient, and interpreted as the absolute difference in 
QALE when moving from the least to most healthy in the population. The RII is the SII divided by 
the mean QALE, and represents the relative change in QALE when moving from the least to most 
healthy. The net inequality impact is the difference between SII or RII value pre- and post-
intervention.  We report the reduction such that positive values indicate interventions estimated to 
reduce health inequality.
We combined the impacts on total population health and health inequality into a single indicator of 
value by first summarising inequality in the distribution using the Atkinson and Kolm indices.(17-19)  
These indices on their own summarise the magnitude of relative and absolute inequality respectively, 
and in essence assign a weight to each individual's QALE that decreases as the individuals rank in 
the distribution of lifetime health increases.  A perfectly equal distribution of health results in an 
inequality index of 0, and a perfectly unequal distribution results in an index equal of 1.  The weights 
and the value of improvements in total population health relative to the value of reduction in 
inequality are determined by an inequality aversion parameter, which signifies the level of concern for 
health inequality.  The higher the inequality aversion parameter, the greater the priority to reducing 
health inequality compared to increasing overall health.  We used inequality aversion parameters 
estimated in a survey of the general public in England that asked respondents to choose between an 
intervention that provided more health overall and one that provided less health overall but reduced 
the gap in health achievement between the richest and poorest.(20)  The estimated inequality aversion 
parameters are 10.95 for the Atkinson  and 0.15 for the Kolm . Given the initial levels of quality-
adjusted life expectancy presented to study participants, these figures suggest a weight for health 
gains to the poorest fifth of people between 6 and 7 times as high as incremental gains to the richest 
fifth.
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hen subtracted from one and multiplied by the mean level of health, the Atkinson and Kolm indices 
can be used to summarise the value of a distribution of health in terms of the equally distributed 
equivalent (EDE) level of health.  The equally distributed equivalent is the level of population health 
(expressed in QALYs), that if provided uniformly to everyone in a population, would yield the same 
amount of social welfare to the distribution of health being evaluated. An intervention estimated to 
reduce health inequality will have an equally distributed equivalent health impact more positive than 
its net population health impact.  Conversely, interventions that increase health inequality would have 
an equally distributed equivalent more negative than their net population health impact, with the 
difference showing the loss of social welfare in terms of QALYs.  
Sensitivity analyses
To assess the sensitivity of the results to the estimated cost per QALY of services that could otherwise 
have been funded (or introduced using resources freed up by cost saving public health interventions) 
we varied the value from its base case of £20,000 between £2,000 to £50,000. We explore sensitivity 
to the level of relative inequality aversion by varying the inequality aversion parameter used to 
calculate the Atkinson index from its base case of 10.95 between 0 and 20.  We also investigated the 
differences in our results when using the costs and health estimates associated with the worst case 
scenario for those interventions where multiple cost-effectiveness results were reported.
Results
The final dataset consisted of 33 guidelines covering 134 discrete interventions. Detail of the included 
guidelines (Table A1), flow diagram (Figure A1) and exclusions for data extraction (Table A2), full 
results by intervention (Table A4) and full results of sensitivity analyses are provided in an online 
supplement.  
Table 1 summarises the net population health and inequality impacts of interventions, and Figure 2 
and Figure 3 show the interventions locations on the health equity impact plane, separated according 
to whether they were recommended by the PHAC.  Estimated SII reductions varied between -0.02 to 
0.36, suggesting that the maximum a single intervention could reduce the gap in QALE between the 
least and most healthy from its baseline value of 13.78 was by 0.36 QALYs, and at most a single 
intervention could increase the gap by 0.02 QALYs.  At the population level of England and Wales, 
the majority of interventions had small impacts on health inequality (interquartile range for change in 
SII -0.0002 to 0.001).  Ten percent of interventions were associated with reductions in SII of 0.06 or 
greater.  Positive correlation was observed between net population health impact and SII reduction 
(Pearson correlation coefficient = 0.94).  The change in Atkinson index indicated improvement in 
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ocial welfare for 73 (86%) of interventions recommended by the PHAC and 15 (31%) of 
interventions that were not recommended by the PHAC.
Table 2 and Figure 4 show the results of full implementation of all recommendations by guideline. 
Eighteen (60%) were estimated to increase total population health and reduce health inequality; four 
(13%) were estimated to reduce total population health and increase health inequality; and eight 
(27%) involved a trade-off.  Estimated net population health benefits range from -1.1 million QALYs 
(NG6) to 10.9 million QALYs (PH50). Health inequality impacts range from an increase in SII of 
0.02 (NG6) to a reduction by 0.23 (PH50).  The guidelines where the value of health gains are 
reduced by the fact that they increase inequality in the distribution of health are PH41 and NG34 
(increase in absolute inequality only), and PH17, PH20 and NG21 (increase in relative and absolute 
inequality).  The equally distributed equivalent indicated that social welfare would increase from 
recommendations in all but four guidelines (PH29, PH31, PH54, NG6), all of which were associated 
with negative changes in population health.  The potential cumulative impact across all guidelines was 
an additional 23,336,181 QALYs in the population of England and Wales and a reduction in SII of 
0.44.  The equally distributed equivalent health from full implementation of recommendations across 
all guidelines was 28,723,776 QALYs, implying that the inequality reduction is equivalent in worth to 
an additional 5.4 million QALYs.
We estimated different measures of relative inequality and absolute inequality, and found little 
disagreement between them.  For two guidelines (PH41 and NG34) relative inequality measured by 
Atkinson index reduced while absolute inequality measured by Kolm index and SII increased, and for 
two more (PH3 and PH24) the SII increased but Atkinson and Kolm indexes indicated a reduction in 
inequality.  The sensitivity analyses indicated that increasing the value of the health opportunity cost 
above £20,000 per QALY had little impact (Figure A2 in online supplement).  However, the 
estimated cumulative reduction in SII fell as the cost per QALY of alternative investments reduced, to 
0.42 using £10,000 per QALY and to 0.27 using £2,000 per QALY.  The ranking of guidelines in 
terms of equally distributed equivalent health impact was sensitive to changes in the inequality 
aversion parameter, with a change of rank observed for 12 out of 30 guidelines when the inequality 
aversion was increased from 0 to a value of 20 (Figure A3 in online supplement).  However, overall 
conclusions about the direction of change in social welfare were less sensitive and changed for only 1 
out of 30 guidelines.  Using worst case estimates for incremental costs and QALYs in general reduced 
estimated reductions in health inequality (Table A3 in online supplement).
Discussion
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10
The method we propose produces quantitative information on health inequality impacts from the 
evidence routinely provided for the formation of public health recommendations.  Equally distributed 
equivalent health calculations place a greater value on health gains if they reduce inequality in 
lifetime health.  This prioritises an additional QALY to someone with low quality adjusted life 
expectancy over an additional QALY to someone with high quality adjusted life expectancy.  New 
public health interventions are often funded with resource that would have been used for alternative 
public health activities, and this method ensures that health opportunity costs contribute to the 
estimates of net health inequality impact.  
The moderate positive correlation between cost effectiveness and health inequality reduction in this 
sample suggests that recommendations based on cost effectiveness alone might coincide with 
decisions that incorporate concern for health inequality, but not always.  The majority of PHAC 
recommendations were for interventions that reduce health inequality; where this is the case focussing 
on population health gains alone routinely undervalues investment in public health interventions.  
This is important where public health interventions compete for funds with downstream healthcare 
interventions, which may have less scope to reduce inequality.    
If health inequalities influence PHAC recommendations, a lower probability of recommendation 
would be expected for interventions that increase population health and increase health inequality 
compared to those that increase population health and reduce health inequality.  Similarly, we would 
expect a higher probability of recommendation for interventions that reduce population health but 
reduce health inequality compared to interventions that reduce population health and increase health 
inequality.  The small sample of trade-offs we found does little to inform this, and we did not search 
for qualitative discussion of inequality in the considerations section of the guidelines.  Overall, we 
found that PHAC recommendations were highly concordant with social welfare.  Some PHAC 
recommendations improved health but increased absolute inequality in health.  Our analysis indicates 
that society values the associated increase in population health associated with these 
recommendations (5.6 million QALYs) sufficiently to accept the increased health inequality (increase 
in SII of 0.005).
We systematically extracted data from published NICE guidelines and used an empirical estimate of 
the socioeconomic distribution of the health opportunity cost to represent the potential harms from 
diverting resources from alternative activities.  However, we made a number of simplifications that 
are worth consideration in future applications of this method.  We did not attempt to characterise 
PHAC considerations regarding the quality of evidence nor the impact of uncertainty.  Our estimates 
represent the maximum possible impact as we did not search for evidence on differential uptake 
between population groups and present our results in terms of full implementation of the 
interventions.  Where interventions are more likely to be utilised in least deprived groups, as can be 
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he case where uptake relies on individual agency, we will have overestimated reductions in health 
inequality.(21, 22)  The method we propose can easily incorporate differential uptake by distributing 
the population health benefits only to the proportion of each group assumed to utilise the intervention.    
We also did not search for evidence of differential efficacy.  Determining the impact of this on health 
inequality impacts is not straightforward as the relationship to average QALY gains may be non-
linear and counterbalanced by interaction with differential baseline risks.  Evidence for differential 
efficacy between population groups can guide the use of full distributional cost effectiveness analysis 
in place of this simplified approach.
The value used to convert costs into health opportunity costs is a significant driver of the results, 
which demonstrates the importance of getting this value right for any formal appraisal process. Since 
opportunity costs fall heaviest on the poorest and least healthy, inequality increases with the health 
opportunity cost for cost increasing interventions. If the value we use is too high, we will have 
overestimated improvements in total population health, reduction in health inequality and 
improvement in social welfare.  The £20,000 per QALY used by NICE for a health sector perspective 
is higher than empirical estimates within the health sector.(11)  The cost per QALY for a public health 
perspective could be lower than the health sector; the median cost per QALY for public health 
interventions considered by NICE is £7,843.(13) The level of health inequality aversion is also 
uncertain and can be difficult to measure without bias. UK estimates range from 5.4 to 28.9.(23, 24)  
However, our results were not particularly sensitive to variation in this parameter.
We based the socioeconomic distribution of the health opportunity costs on the characteristics of 
beneficiaries from NHS spend. Targeting of public health interventions to disadvantaged groups could 
imply that the health opportunity costs fall even more on disadvantaged groups in comparison to NHS 
expenditure, but we did not identify evidence for this.  If true, it implies that we underestimated the 
reduction in health inequality from cost savings and the increase in health inequality from additional 
costs.  Our method assumes that funds used to provide public health interventions would otherwise 
have been spent on health generating activities.  This ignores how opportunity cost may differ where 
public health interventions impose costs across different sectors with interests outside of health 
improvement.  However, previous research has shown that healthcare costs are the predominant 
category of cost impact within NICE public health guidance.(25)  
Previously Owen et al. examined the cost-effectiveness of public health interventions underpinning 
NICE public health guidance.(13, 26)  Our study is the first to examine the health inequality impacts 
of those same interventions, and follows the same principles outlined for full distributional cost 
effectiveness analysis.(7)  McAuley et al. modelled the impact of a range of policies on population 
health and inequality by IMD in Scotland.(27)  They did not assume 100% reach for all interventions, 
but as the assumed equal uptake across population groups their health inequality impacts would be 
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expected to be smaller but in the same direction as our estimates.  However, their analysis did not 
include health opportunity costs.  For public health interventions they found impacts on health 
inequality of similar magnitude and direction to those presented here.  
Future applications of this method should seek to incorporate evidence on differential uptake, and to 
carefully consider the implications where there exists evidence of differential effectiveness between 
socioeconomic groups.  Ongoing research to estimate both the mean and the socioeconomic 
distribution of the health opportunity cost specific to public health investments and to explore how 
this varies across the public sector will boost the application of this method. 
This method is fast, requires little data above that routinely produced to support public health 
guidelines, and provides information about the potential magnitude of health inequality impacts to 
support recommendations.  The Health and Social Care Act of 2012 introduced legal duties for 
decisions in the NHS to be made with due regard to reduce health inequalities.  Our analysis 
demonstrates that a simple distributional cost effectiveness analysis framework is feasible and could 
provide additional information on which to base recommendations for health interventions.  The 
proposed use is within a deliberative decision making process that takes account of factors outside of 
the economic calculations, such as the quality of the underlying evidence.  In the current cost 
constrained funding environment for public health, consideration of the socioeconomic distribution of 
the health opportunity cost is vital to ensure that new investments perform better than existing 
activities for the most disadvantaged.  Showing the location of public health interventions on the 
health equity impact plane could draw attention to, and prompt further examination for, interventions 
found to have negative impacts.(28)  Presenting the results using equally distributed equivalent health 
can demonstrate the added social value of reducing health inequality over and above improvements in 
total population health, and could be a useful tool for advocating increased investment in public 
health.  
Acknowledgments: The authors would like to acknowledge Karl Claxton and Richard Cookson for 
their role in the inception of the method proposed, and Amanda Upton for her role in assisting in data 
extraction.
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Impact Recommended Not recommended % Recommended
Increases total health and reduces inequality 57 (67%) 13 (27%) 84
Increases total health and increases inequality 14 (16%) 2 (4%) 86
Reduces total health and reduces inequality 3 (4%) 2 (4%) 50
Reduces total health and increases inequality 11 (13%) 32 (65%) 26
Overall 85 49 63
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Code Topic N    
 

PH50 Domestic violence and abuse 10,862,451 0.2317 12,890,044 12,524,194
PH15 Coronary heart disease 5,835,560 0.1496 7,876,529 7,568,577
PH41 Walking and cycling 5,329,142 -0.0015 5,421,791 5,309,340
PH35
Type 2 diabetes prevention: population and 
community level
786,051 0.0724 1,866,502 1,734,321
PH45 Smoking: harm reduction 594,011 0.0110 750,737 724,712
PH14 Child smoking prevention 171,359 0.0031 215,036 207,693
PH17 Physical activity in children 169,267 -0.0009 163,623 160,766
PH19 Reducing absenteeism 121,518 0.0009 132,345 128,993
PH24 Preventing and treating alcohol-use disorders 118,338 -0.0009 123,023 119,042
NG22
Older people with social care needs and 
multiple long-term conditions
18,033 0.0048 93,719 84,952
NG32
Older people: independence and mental 
wellbeing
83,144 0.0005 89,281 87,137
NG21 Home care for older people 111,340 -0.0023 88,568 88,356
NG27
Inpatient hospital and community or care home 
transition
82,582 0.0002 87,948 85,872
PH4 Substance misuse interventions for under 25s 64,550 0.0019 80,637 78,126
PH43 Hepatitis B and C testing 56,046 0.0010 69,947 67,673
PH28 Looked-after children and young people 23,757 0.0003 27,551 26,765
PH38 Type 2 diabetes prevention: people at high risk 10,251 0.0001 12,446 12,051
PH23
School-based interventions for smoking 
cessation
4,529 0.0001 7,431 7,043
NG34 Sunlight exposure 5,449 -0.0000 5,583 5,445
PH26 Smoking cessation for pregnant women 3,280 0.0001 4,101 3,965
PH20
Emotional and social wellbeing in secondary 
schools
2,588 -0.0000 2,219 2,197
NG55
Harmful sexual behaviour (HSB) among 
children and young people
1,717 0.0000 2,010 1,951
NG33 Tuberculosis 866 0.0001 1,654 1,553
PH3 STI Infection and Teenage Conception 1,260 -0.0000 1,445 1,397
PH30
Unintentional injuries in the home for under 
15s
-258 0.0000 290 232
PH21 Immunisation programmes 23 0.0000 25 25
PH29
Unintentional injuries: prevention strategies for 
under 15s
-583 -0.0000 -805 -778
PH31
Unintentional injuries on the road for under 
15s
-1,067 -0.0000 -1,323 -1,284
PH54 Physical activity: exercise referral schemes -2,325 -0.0001 -3,584 -3,442
NG6 Excess winter deaths and illness -1,116,696 -0.0167 -1,285,862 -1,250,886
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43 Hepatitis B and C testing
This guideline contributed five interventions to the analysis.  This worked example focussed on one: the use 
of dried blood spot testing in specialist addiction services.
(i) The economic evaluation reported total incremental costs of £917,478 and incremental quality-adjusted 
life years (QALYs) of 63.  
The target population was injecting drug users (IDU), aged 15-59, in contact with specialist services.  The 
economic evaluation submitted to NICE indicated that 0.65% of the population aged 15-59 are current IDU, 
25% of whom are undiagnosed and in contact with specialist addiction services.  We multiply these by the 
2011 UK census figure of 37,899,000 individuals aged 15-59 to obtain a target population size of 61,586.
Note that if per person incremental costs (£14.90) and QALYs (0.001) had been reported, these would have 
been multiplied by population size.
(ii) This guideline targets the diseases Hepatitis B and C, which map to ICD codes B17, B18 B19.
The subgroup sizes are determined using the proportion of NHS activity by gender and ICD code.  We report 
the calculations for females, who constitute 48% of all NHS activity in this ICD code.  The same approach 
applied to males provides the subgroup sizes within the remaining 52%.
The distribution of NHS hospital activity by IMD quintile for females in these ICD codes is, in order from 
most deprived to least deprived, 0.14, 0.11, 0.11, 0.07 and 0.06. 
(iii) The same health opportunity cost of one QALY per £20,000 applies for all interventions. The total 
population cost in terms of health opportunity costs is 	£20,000 = 46 QALYs.
(iv) The distribution of this opportunity cost is the same for all interventions.  In females, the order from most 
deprived to least deprived IMD quintile is 0.14, 0.12, 0.12, 0.09, and 0.08.
(v) Calculation of the distribution of net benefits by index of multiple deprivation quintile (IMD) for females 
from dried blood spot testing for Hepatitis B and C
 IMD IMD IMD3 IMD4 IMD5
(a) Proportion of health benefits 0.14 0.11 0.11 0.07 0.06
(b) Total health benefi (a*63) 8.7 6.8 6.8 4.4 3.7
(c) Proportion of health opportunity costs 0.14 0.12 0.12 0.09 0.08
(d) Total health opportunity costs (c*46) 6.4 5.5 5.5 4.1 3.7
(e) Net benefits (b-d) 2.3 1.3 1.3 0.3 0.0
Note: Health is measured in terms of quality-adjusted life years; IMD1 is the most deprived quintile
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Influence diagram demonstrating how data are combined to estimate the net distributional effect of 
interventions. 
Footnote 1. Intervention costs are converted into health opportunity costs using a cost-effectiveness 
threshold of £20,000 per QALY. 
160x139mm (150 x 150 DPI) 
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Table A V WXYZ[\nes in the analysis ]\^_`sYZ[ a^a]\ number of included interventions and number 
recommended
Interventions in guideline
Code Topic Included Recommended
cefg Home care for older people 1 1
ceff hijkl mknmik with social care needs and multimik inprtuklv conditions 1 1
cefw Inpatient hospital and community or care home transition 4 3
cexz hl{i |k{ith promotion 2 0
cexf hijkl mknmik }~pjkmkpjkpe and mental weiik~pr 2 2
cexx
Tuberculosis 6 4
cex pi~r|u kmnlk
5 2
ce {lvi k{i k|{~nl Ł {vnpr |~ijlkp {pj npr mknmik 2 2
ce k ~pukl jkaths and illness 14 5
PH3  pku~np {pj kkp{rk ption 2 2
PH4 u{pk visuse interventions for under 25s 4 1
PH14 Child smokipr mlkkpu
~
np 2 2
PH15  t vnkl 22 18
PH17 Physical activity in children 4 1
PH19 kj~pr {bsenteeism 3 3
PH20 vnu~onal and social weiik~pr ~p kondary schools 1 1
PH21 Immunisat
~
np mlnrl
{
vvk 2 2
PH23 
|
nnit
{
kj
~
puklkpu
~
np nl vn
~
pr

kssation 1 1
PH24 lkkpu
~
pr
{
pj ulk
{
u
~
pr
{
icohol-use disorders 1 1
PH26 vn~pr kssat~np nl mlkrp{pu nvkp 5 5
PH28 nnkjt{uer children apj npr mknmik 2 2
PH29 p
~
pukpu
~
onal injuries
}
 prevention stratkr
~
k nl pjkl g 1 1
PH30 p
~
pukpu
~
onal injuries ip u
|
k
|
nvk
} ~
nterventions for under 15s 1 1
PH31 p
~
pukpu
~
onal injuries on the road for under 15s 4 2
PH32 Information to prevent skin cancer 8 0
PH35 Diabetes prevention 5 3
PH38 Diabetes prevention 3 1
PH40 n
~{
i
{
nd emotional weii

k
~
pr
}
k
{
rly years 4 0
PH41 
{
i
~
pr
{
pj



i
~
pr 6 4
PH43 Hepatit
~
 
{
pj  uku
~
pr 5 5
PH45 vn~pr}|{rm reduction 4 4
PH50 Domestic vinikpk {pj {k} viu~t{rkp nl~pr 2 2
PH54 Physical acu~~u} kkl~k lkkll{i schemes 4 3
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Noteﬀfifl°–†fi‡·µ¶•‡‚  Institute of Heal´¹ ³·º °³»¼ ±½¾ellence; ﬁ¿À`†´ˆ‡‚ ﬂﬃy adjusted life year
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(
Table A3ò óôõõö÷öøù) *)+w))n *),+ -n. worst case estimates of cost-effectiveness. 
/0;del;ne Intervention Recommended
!"#"$%  
(best)
!"#"$%  
(worst)
Difference
úûüü
ýþßO ßnß  ßc multidisciplinary 
assessment and case   n  nt intervention
Y<= 11 187 -904
PH15 Dentist-based interventions Y<= 11		 6	
	 -

>?15 @ree mobile phones No 61	 1	 -66
PH15 @ree NRT No 
8ü6 6üü -ü1		
PH15 I   ßþ ß  ans Yes ü1
 -1 -ü1

PH15 Pharmacist-based interventions Yes 
1 	ü -

PH15 Pharmacist-based interventions (deprived area) Yes
ü111 1	6	 -ü8

PH15 Proactive telephone counselln Yes üüü1 1
ü -ü118
PH15 Recruit
 nß ß mþß  n nm
Yes
ü86
738
-ü6	

PH15 S l   ßn a n Americans) Yes 114 0 -114
PH15 Pharmacist-based interventions (CHD) Yes 659 -28 -687
PH24 Snn  nd brief intervention Yes 103 -94 -197
PH28 Transition support services (females) Yes 11 -5 -16
PH28 Transition support services (males) Yes 51 15 -36
PH3 Accelerated Partner Therapy Yes 1 0 0
PH3 Counsellin Yes 3 -9 -12
PH32 Multicomponent in community No -1 -1 0
PH32 Multicomponent in healthcare settn No -3 -3 0
PH32 V


 l  


ce No 0 -8 -8
PH4 L ll ß nn Yes 180 22 -158
PH41
L
 
 l

n
Yes 9 -22 -31
PH41 Pedometer Yes 343 -13 -356
PH41 Travel
S
mart Yes
ü
1

157
-ü661
PH45
Quit and substit
þß

ß

l

n-ß
rm nicotine use 

ß

n
ric professional behavioural support
Yes
8ü	
29
-8ü
PH45
Temporary abstinence or re
þ

 

n

ß

specialist services behavioural support
Yes 630
-	
6 -8ü16
PH54 E

se referral scheme No -69 -61 9
PH54 Ese referral scheme (depression) Yes -11 -12 -2
PH54 E

se referral scheme (hypertension) Yes -32 -33 -1
PH54 Ese referral scheme (obese) Yes -14 -15 -2
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BCgure A2: ﬀﬁﬂﬃD EIDfare rank order ﬁ! "ﬂ# $%ﬃ&"'ﬃ(") '"!* #nd side when only total health benefit 
is considered (no inequality av"r+ﬃﬁ(,. rﬃ$#* #(& +ﬃ&" whe( *#"r" ﬃ+ 'r$" concern for health 
inequality
Note: /0 234579;ity aversion equates to the parameter E i3 <=4 ><?23@03 A4;B9C4 D3F4G @4< <0 HJ K0C =2M= 234quality aversi03o
E:$A
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K
Table A4` bcdfhjfntion characdfhtkdtpk qs fudhwpdfx ybz{ |}~tc health interventions
Topic Intervention Code QALY Cost Population Recommended
Home care for older people
 are services provided as part of care pac Ł
people l     Ł  Łch
 0.02 £  LMN

Ł 
OQRh
N
ocial care needs and multiple 


Ł
 conditions





Ł

Ł
c multidisciplinary assessment and case 

ment intervention

0.17
£

 
 ¡
 LMN
Inpatient hospital and community or care home 
transition
Multidisciplinary palliative care teams  0 £ ¢  LMN
Inpatient hospital and community or care home 
transition
¤Ł¥ ¦

Ł

 ¦Ł  ¦

Ł  0.47 £§ § LMN
Inpatient hospital and community or care home 
transition
¤Ł¥ ¦

Ł

 ¦Ł Ł 
e

¡ 0.02 
£ ¢ LMN
Inpatient hospital and community or care home 
transition
¦ Ł

Łc intervention for older people Ł¦
with undifferentiated confusion

 0 £¢¡¡  No

Ł th promotion  lth counselli ¡ 0.0002 £§  No

Ł 
th promotion 




 
lth counselli
 
¡

0.0003
£
 
¢
 
§
No

Ł ¨e and mental we© Internet and computer tŁ rvention ¡ 0.02 £¡ ¡ LMN

Ł ¨M
Snd mental we
©
ª
Ł¦ ŁŁ
mes

¡

0.04 
£
¡

 ¡


 LMN
Uuberculosis «© ¬Ł¥  ¦Ł ­ess) ¡¡ 0.083 £¢ ¡ LMN
U
uberculosis
¤ ¦


ment (homeless)

¡¡

0.093 
£
¡



33
LMN
U
uberculosis
«© ¬

Ł¥ ¦Ł   ¦

ent 
(homeless)
¡¡¡
0.138 £¡§  ¡ LMN
Uuberculosis «© ¬Ł¥  ¦Ł ­Ł¦Ł¦® ¡¡ 0.013 £   §¢§ No
Tuberculosis
¤ ¦
ment (prisoners)
¡¡§
0.013 £¡ 179 LMN
U
uberculosis
«© ¬

Ł¥ ¦Ł   ¦


ent 
(prisoners)

¡¡

0.018 
£
¡¡

 
§¢§
No





¯
¦

Ł
Informati
 ŁŁ Ł ¦
hildren

¡

0
£§ 

§
No





¯
¦

Ł °

 
¡
 0 £ ¢¡¢ No





¯
¦

Ł
±

¯

essa
 
¡

¡ 0.0001
£

§


¡ No





¯
¦

Ł TailŁ ¦¦¦ ¡ 0.0003 £ § LMN





¯
¦

Ł
VS
NN
X
M
dia ca
 
¡
§
0.0001
£ §
¡

 
 LMN
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Z
²³´µ¶·¸ ¹º»·³¸ ¼º½³¾¿À·´ Á²ÂÃÄ ³µÀÅÆ Ç½¿¸dren 
³ÅÈ ÉÀ·ÅÆ ÊºÀÊ¸º
 Multi-systemic therapy ËÌÍÍÎÏ 0.061 ÐÑÒÓÍÍÏ ÔÓÕÖÒ [\]
²³´µ¶·¸ ¹º»·³¸ ¼º½³¾¿À·´ Á²ÂÃÄ ³µÀÅÆ Ç½¿¸dren 
³ÅÈ ÉÀ·ÅÆ ÊºÀÊ¸º
×ÀÆÅ¿Ø¿ve behavioural therapy ËÌÍÍÎÕ 0.035 ÐÑÔÓÙÔÚ ÔÓÕÖÒ [\]
Û»Çº¹¹ Ü¿ÅØº´ Èº^_`] ^nd illness ²Àµº ºÅº´ÆÉ ºfficiency intervention ËÌÝÎÏ 0.048 ÑÏÓÞÍÙ ÙÒÍÓÕÙÖ [\]
Û»Çº¹¹ Ü¿ÅØº´ Èº^_`] ^
nd illness
²Àµº ºÅº´ÆÉ º
fficiency intervention
ËÌÝÎÏÖ
0.002
ÑÏÓÔÒÞ ÝÓÖÒÒÓÖÙÕ [\]
Û»Çº¹¹ Ü¿ÅØº´ Èº^_`] ^nd illness ÑÕÖÖ ¶·º¸ ¹·¼¹¿ÈÉ ¿ÅØervention ËÌÝÎÏÏ 0.001 ÑÏÓÏÕÚ ÝÓÖÒÒÓÖÙÕ No
Û»Çº¹¹ Ü¿ÅØº´ Èº
aths and illness
²Àµº ºÅº´ÆÉ Ê¸
us fuel subsidy
ËÌÝÎÏÕ
0.002
ÑÕÓÞÍÙ ÝÓÖÒÒÓÖÙÕ
No
Û»Çº¹¹ Ü¿ÅØº´ Èºaths and illness ²Àµº ºÅº´ÆÉ ºfficiency intervention ËÌÝÎÏÞ 0.001 ÑÏÓÔÞÖ ÔÓÍÔÍÓÔÖÔ [\]
Û»Çº¹¹ Ü¿ÅØº´ Èº^_`] ^
nd illness
ÑÕÖÖ ¶·º¸ ¹·¼¹¿ÈÉ ¿ÅØ
ervention
ËÌÝÎÏÔ
0.001
ÑÏÓÏÕÙ ÔÓÍÔÍÓÔÖÔ
No
Û»Çº¹¹ Ü¿ÅØº´ Èºaths and illness ²Àµº ºÅº´ÆÉ Ê¸us fuel subsidy ËÌÝÎÏÍ 0.002 ÑÕÓÞÏÏ ÔÓÍÔÍÓÔÖÔ No
Û»Çº¹¹ Ü¿ÅØº´ Èº
aths and illness
ÑÕÖÖ ¶·º¸ ¹·¼¹¿ÈÉ ¿ÅØ
ervention
ËÌÝÎÕ
0.032
ÑÏÓÏÕÕ ÙÒÍÓÕÙÖ
No
Û»Çº¹¹ Ü¿ÅØº´ Èºaths and illness ²Àµº ºÅº´ÆÉ Ê¸us fuel subsidy ËÌÝÎÞ 0.073 ÑÕÓÕÏÖ ÙÒÍÓÕÙÖ No
Û»Çº¹¹ Ü¿ÅØº´ Èº
aths and illness
²Àµº ºÅº´ÆÉ º
fficiency intervention
ËÌÝÎÔ
0.006
ÑÏÓÔÍÝ ÏÓÝÒÒÓÏÕÒ [\]
Û»Çº¹¹ Ü¿ÅØº´ Èº^_`] ^nd illness ÑÕÖÖ ¶·º¸ ¹·¼¹¿ÈÉ ¿ÅØervention ËÌÝÎÍ 0.004 ÑÏÓÏÞÖ ÏÓÝÒÒÓÏÕÒ No
Û»Çº¹¹ Ü¿ÅØº´ Èº
aths and illness
²Àµº ºÅº´ÆÉ Ê¸
us fuel subsidy
ËÌÝÎÝ
0.008
ÑÕÓÞÏÔ ÏÓÝÒÒÓÏÕÒ
No
Û»Çº¹¹ Ü¿ÅØº´ Èºaths and illness ²Àµº ºÅº´ÆÉ ºfficiency intervention ËÌÝÎÚ 0.001 ÑÏÓÍÖÖ ÕÓÒÝÍÓÏÞÏ [\]
Û»Çº¹¹ Ü¿ÅØº´ Èº^_`] ^
nd illness
ÑÕÖÖ ¶·º¸ ¹·¼¹¿ÈÉ ¿ÅØ
ervention
ËÌÝÎÙ
0.0007
ÑÏÓÏÞÖ ÕÓÒÝÍÓÏÞÏ
No
Û»Çº¹¹ Ü¿ÅØº´ Èºaths and illness ²Àµº ºÅº´ÆÉ Ê¸us fuel subsidy ËÌÝÎÒ 0.002 ÑÕÓÞÍÖ ÕÓÒÝÍÓÏÞÏ No
b
`
dfd smoki
ÅÆ Ê´º¾ºÅØ¿ÀÅ
Mass media ca
µÊ³¿ÆÅ
PH14.1 0.1
ÑÍ ÞÓÏÔÚÓÖÙÒ
Yes
Child smokiÅÆ Ê´º¾ºÅØ¿ÀÅ Point of sale intervention PH14.2 0.01 ÑÏÚ ÞÓÏÔÚÓÖÙÒ Yes
×²
ß
Ð ÂµÀ
à
º´¹
 Recruit
¿ÅÆ ¹µÀ
à
º´¹ ¶´Àµ ÇÀµµ·Å¿
ty PH15.10 1.7
ÑÏÚ ÏÖÓÕÏÖÓÚÚÖ
Yes
×²
ß
Ð ÂµÀ
à
º´¹  RecruitµºÅØ ØÀ áâ·¿Ø ³ÅÈ ã¿Åá PH15.11 0.69 ÑÍÞ ÏÖÓÕÏÖÓÚÚÖ Yes
×²
ß
Ð ÂµÀ
à
º´¹
äß
¹µÀ
à
º´¹ Ø½´À·Æ½ ÀØ½º´ µº
ans PH15.13 0.55
ÑÝ ÏÖÓÕÏÖÓÚÚÖ
Yes
×²
ß
Ð ÂµÀ
à
º´¹  Dentist-based interventions PH15.15 0.38 ÑÚÍ ÏÖÓÕÏÖÓÚÚÖ Yes
×²
ß
Ð ÂµÀ
à
º´¹
 Drop-in community-based sessions PH15.16 0.03
ÑÕÕ ÏÖÓÕÏÖÓÚÚÖ
Yes
×²
ß
Ð ÂµÀ
à
º´¹  Pharmacist-based interventions (smokers) PH15.17 0.23 ÑÏÕÏ ÏÖÓÕÏÖÓÚÚÖ Yes
×²
ß
Ð ÂµÀ
à
º´¹
 Free NRT PH15.20 0.21
ÑÝ ÏÖÓÕÏÖÓÚÚÖ
No
×²
ß
Ð ÂµÀ
à
º´¹ ÂÀÇ¿³¸ µ³´
à
ºØ¿ÅÆ PH15.21 0.02 ÑÏ ÏÖÓÕÏÖÓÚÚÖ Yes
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j
åæç è éêëìíîï ðëîìñòóôí ïêëìõö÷ ôíïïóøõëö ù õncentives PH15.22 0.55 úûû üýþßüýþ11ý kop
åæç è éêëìíîï
C 
õïó
 
óöøó÷í
 
éëôõóò êóîìíøõö÷
C
ó
a
îõ
qrv ry
oricans) PH15.24 0.07 ú£ 4ß£þßû kop
åæç è éêëìíîï
C 
õïó
 
óöøó÷í
 
zo
q
ruitment at pediatric unit PH15.25 0.14 úüûû 4þ99 kop
åæç è éêëìíîï
C 
õïó
 
óöøó÷í
   
æé ééé
C 
íñîõ

íd men) PH15.26 0.43 úü ££1þß44 kop
åæç è éêëìíîï
C 
õïó
 
óöøó÷í
   
æé ééé
C 
íñîõ

íd women) PH15.27 0.38 úü

1ü1þ

ûß kop
åæç è éêëìíîï
C 
õïó
 
óöøó÷í
  {harmacist-based interventions (deprived area) PH15.28 0.77 úüûü üþý4þ£1 kop
åæç è éêëìíîï
C 
õïó
 
óöøó÷í
 
|RT prescription (deprived area) PH15.30 0.39 úß9ý üþ

ý
4
þ
£
1 Yes
åæç è éêëìíîï
C 
õïó
 
óöøó÷í
  
îõí
a
õntervention for low iöôëêí ñîí÷öóöø nëêín PH15.31 0.37 úßüü ü9þû1ý No
åæç è éêëìíîï  Free mobile phones PH15.32 1.94 ú
£
üýþßüýþ11ý No
åæç è éêëìíîï
C 
õïó
 
óöøó÷í
   Proactive telephone support for pre÷öóöø nëêíö PH15.33 0.06 úü4ý 1þ£ûß No
åæç è éøóøõö ïí  Pharmacist-based interventions (CHD) PH15.34 0.08 úß9ý ßþ9ýýþýýý Yes
åæç è éêëìíîï  Interventions at cervicóò ïôîííöõö÷ PH15.37 0.21 úü£ üýþßüýþ11ý Yes
åæç è éêëìíîï  Nurse run clinics PH15.6 0.58 úû9 üýþßüýþ11ý Yes
åæç è éêëìíîï  Proactive telephone counseòòõö÷ PH15.8 0.57 úûß üýþßüýþ11ý Yes
Physical activity in children ðóòìõö÷ ï PH17.1 0.03 úüß
4
1þüüßþýûý Yes
Physical activity in children Dance classes PH17.2 0.002 úû£ 1þüüßþýûý No
Physical activity in children Fîíí ï
n
õêêõö÷ PH17.3 0.0001 úû 1þüüßþýûý No
Physical activity in children Community sports scheme PH17.4 0.0002 úü 1þüüßþýûý No
Rí ôõö÷ ó
bsenteeism ðëîìñòóôe intervention PH19.1 0.12 èú9ý4 û9þýýý Yes
Rí
 
ôõö÷ óbsenteeism Physical activity and education PH19.2 0.06 ú11 û9þýýý Yes
Rí ôõö÷ ó
bsenteeism ðëîìñòóôe interventõëö ù ñi	ïõôóò óôtivity and education PH19.3 0.44 èúýý û9þýýý Yes
Eêëøõonal and social weòòíõö÷ õö ïíôondary 
schools
Classroom intervention / peer mediation to prevent bulò	õö÷ PH20.1 0.002 úü

9þß9
4
þ
£
1û Yes
Immunisatõëö ñîë÷îóêêíï Iöôîíóïõö÷
a
õrst dose ôë

íîó÷í øë üýý
 PH21.1 0.002 èúß ßþ
4
üû Yes
Immunisatõëö ñîë÷îóêêíï Iöôîíóïõö÷ ßö  øë 4øi  ëïíï øë üýý
 PH21.2 0.007 èú1 ßþ4üû Yes
éôiëëòèóïí
 
õöøíî

íöøõëöï
a
ëî ïêëìõö÷ ôíssation Gíöíîõô ïôiëëòèóïí
 
ñîë÷îóêêí PH23.1 0.003 ú
4
1þû
4
1þ
£
ýý Yes
P
îí

íöøõö÷ óö
 
øîíóøõö÷ óòcohol-use disorders éôîííöõö÷ ónd brief intervention PH24.2 0.002 èúü ûßþû4þ£14 Yes
éêëìõö÷ ôíssatõëö
a
ëî ñîí÷öóöø
n
ëêíö åë÷öõøõve behaviour strate÷õíï PH26.1 0.032 úüß

1

þý

Yes
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}
S ~~ S   26.2 0.007 ﬀﬁﬂ 7ﬃﬂﬃﬃ ~
S ~~

dbac 26.3 0.049 ﬀ!7 7ﬃﬂﬃﬃ ~
S ~~ rds PH26.4 0.111 -ﬀ"ﬁ 7ﬃﬂﬃﬃ ~
S ~~ 

rmacotherapies PH26.5 0.032 ﬀ7# 7ﬃﬂﬃﬃ ~
L$-r children a$ %& ' Transition support services (males) PH28.1 0.61 -ﬀ7ﬃ"(ﬃ (
#
"
#
~
L$-r children a$ %& ' Transition support services (females) PH28.3 0.38 -ﬀﬁ)*ﬁ" ))!7 ~
U
onal injuries: prevention strat 
under 15s
ﬁﬂ
2
s i  &'% reas PH29.1 0.0003 ﬀ## ﬁ#"ﬂﬂﬂﬂ ~
S
+, ,
 $
+
 Conception Accelerated Partner Therapy PH3.1 0.003 ﬀﬁ* ()(("ﬃ Yes
S
+, ,
 $
+
 Conception Counselli PH3.3 0.005 ﬀ
#
ﬃ (
)
(("ﬃ Yes
U
onal injuries i  : nterventions for 
under 15s
Free smoke alarms PH30.1 0.0001 ﬀ) (!"ﬃ#7) Yes
U
onal injuries on the road for under 15s M.$ y routes PH31.1 0.002 ﬀ"ﬂﬁ #ﬂ7"ﬂﬂﬂﬂ No
U
onal injuries on the road for under 15s Mandatory 20m
2
 p' &'y area) PH31.2 0.00003 ﬀ
#) *
ﬃﬂﬂﬂﬂ No
U
onal injuries on the road for under 15s Mandatory 20m 2 p &'y area) PH31.3 0.00014 ﬀ#) ﬁ#"ﬂﬂﬂﬂ Yes
U
onal injuries on the road for under 15s A$/% ﬁﬂ
2
 PH31.4 0.00002 ﬀ
#
"
)
7"ﬂﬂﬂ Yes
Information to prevent skin cancer V0' $/ce PH32.1 0.0001 ﬀ# 7##ﬁﬂ"ﬂ No
Information to prevent skin cancer Multicomponent in work-setti PH32.11 0 ﬀ"ﬁ
)#

!
77
*
ﬃﬁ No
Information to prevent skin cancer V0' $/ce PH32.3 0.0001 ﬀﬁ #ﬃ!7#"ﬂ No
Information to prevent skin cancer Provision of shade PH32.4 0 ﬀﬁ
)
ﬂﬃ
)
7ﬁﬂ No
Information to prevent skin cancer Multicomponent in beaches and pools PH32.5 0 ﬀﬁﬂ ﬁﬃﬃ!*"ﬁ No
Information to prevent skin cancer Multicomponent in community PH32.7 0 ﬀ
#
ﬃﬃ
**
ﬂ
)
ﬃ No
Information to prevent skin cancer Multicomponent in educational sett PH32.8 0 ﬀ( )(ﬃﬂ"#ﬂ No
Information to prevent skin cancer Multicomponent in healthcare sett PH32.9 0 ﬀ
#
ﬁ
#
7
!
ﬂ
!
7
*
No
Diabetes prevention 3$&ion to increase & $ / ke PH35.1 0 ﬀ(( 7*ﬃ(((7 No
Diabetes prevention  Dietary education / c '' PH35.2 0.013 ﬀ
##
7
*
ﬃ(((7 Yes
Diabetes prevention 5  $ &' PH35.3 0 ﬀﬂ 7*ﬃ(((7 No
Diabetes prevention  Multi-component small scale PH35.4 0.138 ﬀ7
*
7
*
ﬃ(((7 Yes
Diabetes prevention  Multi-com ' le PH35.5 0.127 ﬀ#! 7*ﬃ(((7 Yes
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10
Diabetes prevention 68;< = >?@>B DbHJK = NO QTWXh intensive intvn) PH38.1 0.012 YJZJ @B[\[B]>^ Ł



 prevention 68;< = >B DbHJK = >?]>O QTWXh intensive intvn) PH38.2 0.021 Y@Z^ @B[\[B]>^ No
Diabetes prevention 68;< = ^?\>B DbHJK = >?\O QTWXh intensive intvn) PH38.3 0.039 Y^\@ @B[\[B]>^ No
<
_
b
`
X
cd
K
e fisuse interventions for under 25s 6Wge `hWjj` XlcWdWdk PH4.1 0.019 Y@> ZB>\NBJ>> Ł
<
_
b
`
X
cd
K
e f


nterventions for under 25s <
c
m o
e`
qW
l`
X PH4.3 0.021 YJBr[[ ZBZ>JB]r> No
<
_
b
`
X
cd
K
e fisuse interventions for under 25s Teacsel XlcWdWdk PH4.4 0.002 Y@ZN \BJJ@B[>[ No
<
_
b
`
X
cd
K
e f
isuse interventions for under 25s The Abecedarian Project PH4.5 0.04 Y\B][[ ^B@rrB^Z[ No
<
t
KW
cj cnd emotional wejjbeWdku ecrly years veehjy home visits PH40.1 0.032 Y@B\JJ @JBJZN No
<
t
KW
cj c
nd emotional we
jj
b
e
W
dku ec
rly years <
_le
<X
cl
X w
tkd
WXW
td gtl
H
ke
> PH40.2 0.354 xYJ[BN>N @JBNN[ No
<
t
KW
cj cnd emotional wejjbeWdku ecrly years <_le <XclX Hke Z QZ mecrs) PH40.3 0.07 YJB[>r @@B^^N No
<
t
KW
cj c
nd emotional we
jj
b
e
W
dku ec
rly years <
_le
<X
cl
X H
ke
Z Q> m
ec
rs) PH40.4 0.372 xYNBr>r @@B^^N No
vcjh
W
dk cdy
KmK
j
W
dk Multi comztdedXu KmKjWdk yeftd`XlcXWon towns PH41.1 0.0062 YZ[ >@B@\NB^@J No
vcjh
W
dk cdy
KmK
j
W
dk
Multi com
ztded
X
u `_`
X
c
W
dc
b
j
e travel towns PH41.2 0.044 Y^\ >@B@\NB^@J No
vcjh
W
dk cdy
KmK
j
W
dk Travel<mart PH41.3 0.093 Y@> >@B@\NB^@J Ł
vcjh
W
dk cdy
KmK
j
W
dk 
dometer PH41.6 0.359 Y@N] ^B[@rBr\Z Ł
vcjh
W
dk cdy
KmK
j
W
dk
6
ey
T
cjh
W
dk

41.7 0.025 Y^\ ^B[@rBr\Z Ł
vcjh
W
dk cdy
KmK
j
W
dk {e
X T
cjh
W
dk heez
T
cjh
W
dk


41.9 0.020 Y>> ^B[@rBr\Z Ł

patitW` | cdy w Xe`XWdk Dried blood spot testWdk Wd `zeKWcjist addiction services  PH43.1 0.001 YJ> NJB>]N Ł

patitW` | cdy w Xe`XWdk Dried blood spot testWdk Xt zlW`td `el}WKe` PH43.2 0.0002 YJ^ \>B\r] Ł

patitW
` | cdy
w X
e`
XW
dk
{8
ey_
K
c
XW
td cdy zc
W
y
X
clke
X
ey
X
e`
XW
dk tg gtlfel
~; Z[x>^
years old
PH43.3 0.0027 YZ\ rJBJ>[ Ł

patitW
` | cdy
w X
e`
XW
dk
w
c`e g
W
dy
W
dk
PH43.4 0.0022 Y^N Z^]B]][ Ł

patitW` | cdy w Xe`XWdk wc`e gWdyWdk PH43.5 0.163 Y^> Z^]B]][ Ł
<
fth
W
dkusc
 duction w; TWX
s kedel
WK professi
tdcj |
< PH45.1 0.1 xYJ^N J[B@J[B\\[ Ł
<
fth
W
dkusc
 duction
uit and substit_Xe TWXs jtdkxXerm nicotine use wiXs kedelWK
zltge``
W
tdcj |
<
PH45.2 0.114 Y@\^ J[B@J[B\\[ Ł
<
fth
W
dkusc
 duction
Temporary abstinence or re
y_Ke `fthWdk TWXs `zeKW
alist 
`el
}WK
e` |
<
PH45.4 0.021 YJNr J[B@J[B\\[ Ł
<fthWdkusc 
duction Reduce a
ft_dX `fthWdk TWXs `zeKW
alist services
|<
PH45.6 0.021 YJNr J[B@J[B\\[ Yes
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
omestic vi  Ł Łncy 

Independent domestic violence advisors PH50.1 0.08   
omestic vi  Ł Łncy 

ve trauma t  d women PH50.2 1.02    
hysical ac¡ ¢ ¤ schemes ¥¢se referral scheme (healthy) PH54.2 0.007 ¦   §¨© No
Physical ac
¡ ¢ ¤
 schemes
¥¢
se referral scheme (obese) PH54.4 0.008
¦  ¨¦ § ¨ 
hysical ac¡ ¢ ¤ schemes ¥¢se referral scheme (hyp) PH54.6 0.007 ¦ ¨   §¦ 

hysical ac
¡ ¢ ¤
 schemes
¥¢
se referral scheme (dep) PH54.8 0.009
¦  
ª
¦©§ 
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12
Table A5« ¬­®¯°±²ity impact of interventions
Topic Code NHB !1 ! Impact !"#"$% &%2345.'
!"#"6$7 &7234.'
Welfare 
rank 
&%23'
Welfare 
rank 
&%23'
Rank 
change
Home care for older people ³´µ¶·¶ ¶¶¶¸¹º» -0.0023 0.0000
¼½
¾¾¸¿À¾ ¾¾¸¹¿À 36 43 -7
ÁÂÃÄÅ ÆÄÇÆÂÄ with social care needs and multiÆÂÄ ÂÇÈÉÊËÄÅÌ 
conditions
³´µµ·µ
Í
¹¸
ÍÍ
µ
0.0048 0.0001
¼¼
Î
¹¸
Í
¶
Î
¾º¸
Î
¿µ
54 37 17
Inpatient hospital and community or care home transition
³´µ
Í
·¶ ¶
Í
¸¾
Î
»
0.0003 0.0000
¼¼
µ»¸Àµ
Í
µ»¸»Àµ
55 57 -2
Inpatient hospital and community or care home transition ³´µÍ·µ ¹¹¸Íºº -0.0004 0.0000
¼½
¹¹¸¶À¹ ¹µ¸¿»µ 45 54 -9
Inpatient hospital and community or care home transition
³´µ
Í
·¹ ¹»¸
Î
º¾
0.0003 0.0000
¼¼
¹º¸¶¿¾ ¹¹¸¹»¾
47 52 -5
Inpatient hospital and community or care home transition ³´µÍ·º Ê¹¸¿º¿ -0.0001 0.0000 -- Êº¸»¾¾ Ê¹¸ÎÍÀ 108 108 0
ÁÅÏÂ ÐÄÏÂth promotion
³´¹»·¶
Ê
¿¸¶¹µ
-0.0001 0.0000 -- Ê¿¸Î»À Ê¿¸Íº¿ 111 110 1
ÁÅÏÂ ÐÄÏÂth promotion ³´¹»·µ -719 0.0000 0.0000 -- -826 -803 98 97 1
ÁÂÃÄÅ ÆÄÇÆÂÄÑÒÈÃÄÆÄÈÃÄÈÓe and mental weÂÂÔÄÒÈÉ
³´¹µ·¶ ¶µ¸¶À»
-0.0004 0.0000
¼½
Î
¸»¾º
Î
¸»¿
Î 58 62 -4
ÁÂÃÄÅ ÆÄÇÆÂÄÑÒÈÃÄÆÄÈÃÄÈÓe and mental weÂÂÔÄÒÈÉ ³´¹µ·µ ¶¿º¸¶µ¾ 0.0014 0.0000
¼¼
¶À
Î
¸º
ÍÍ
¶À¿¸µ¶º 32 35 -3
Tuberculosis
³´¹¹·¶
533 0.0001 0.0000
¼¼
¶¸Àº¹ ¶¸¿¹
Í 74 72 2
Tuberculosis ³´¹¹·µ 9 0.0000 0.0000
¼¼
19 18 84 85 -1
Tuberculosis
³´¹¹·¹ ¶¸¹¶¶
0.0001 0.0000
¼¼
¹¸µµ
Í
¹¸»¹À
71 68 3
Tuberculosis ³´¹¹·º -112 0.0002 0.0000
½¼
¹¸¿¶¶ ¹¸µ»¶ 73 65 8
Tuberculosis
³´¹¹·¿
14 0.0000 0.0000
¼¼
24 23 82 83 -1
Tuberculosis ³´¹¹·À µ¸ÎÀÀ 0.0003 0.0000
¼¼
¾¸¿Í¾ ¾¸»º¶ 64 60 4
ÕÖÈÂÒÉÐË Ä×ÆÇØÖÅÄ
³´¹º·¶
-481 0.0000 0.0000 -- -554 -539 94 94 0
ÕÖÈÂÒÉÐË Ä×ÆÇØÖÅÄ ³´¹º·µ -887 0.0000 0.0000 -- Ê¶¸»µ¹ -995 99 100 -1
ÕÖÈÂÒÉÐË Ä×ÆÇØÖÅÄ
³´¹º·¹
Ê
¶¸ÀÀ¿
0.0000 0.0000 -- Êµ¸¶Îµ Êµ¸¶¶Í 104 105 -1
ÕÖÈÂÒÉÐË Ä×ÆÇØÖÅÄ ³´¹º·º 64 0.0000 0.0000
¼½
37 39 80 87 -7
ÕÖÈÂÒÉÐË Ä×ÆÇØÖÅÄ
³´¹º·¿ ¿¸¹¾º
0.0000 0.0000
¼½
¿¸¿ºÀ ¿¸º»À
61 64 -3
Ù
ÏÅÌ
Ú
ÖÂ ØÄ×ÖÏÂ ÔÄÐÏ
Û
ÒÇÖÅ
ÜÙ
Õ
ÝÞ
ÏÌÇÈÉ ÓÐÒÂÃÅÄÈ ÏÈÃ
ß
ÇÖÈÉ
people
³´¿¿·¶ µ¸µÀÍ
0.0000 0.0000
¼¼
µ¸À¿¶ µ¸¿Íº
67 70 -3
ÙÏÅÌÚÖÂ ØÄ×ÖÏÂ ÔÄÐÏÛÒÇÖÅ ÜÙÕÝÞ ÏÌÇÈÉ ÓÐÒÂÃÅÄÈ ÏÈÃ ßÇÖÈÉ
people
³´¿¿·µ ¶¸¶À
Í 0.0000 0.0000
¼¼
¶¸¹À¾ ¶¸¹µ
Í 72 75 -3
à
×ÓÄØØ
á
ÒÈËÄÅ ÃÄaths and illness ³´À·¶ Ê¶¾¸¶Íº -0.0003 0.0000 -- Êµ¶¸À»¹ Êµ»¸Î¿º 115 115 0
Page 33 of 38
http://mc.manuscriptcentral.com/mdm
Medical Decision Making
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
For Peer Review
13
âãäåææ çèéêåë ìåaths and illness íîïðñò óôôõöõ÷ø -0.0069 -0.0001 -- óõñïöùúò óõòñöûûô 131 131 0
âãäåææ çèéêåë ìå
aths and illness
íîïðññ ó÷÷øöñûô
-0.0052 -0.0001 -- ó÷ûñö÷úø ó÷øòöõøõ 129 129 0
âãäåææ çèéêåë ìåaths and illness íîïðñù óúòïöùúô -0.0109 -0.0002 -- óøñúöúùô óúûõöñôù 133 133 0
âãäåææ çèéêåë ìå
aths and illness
íîïðñ÷ ó÷ñûöûûï
-0.0044 -0.0001 -- ó÷ï÷öñõò ó÷õ÷öúñô 128 128 0
âãäåææ çèéêåë ìåaths and illness íîïðñô óùõ÷öñúû -0.0035 -0.0001 -- óùøøöùùò óùøòöïõù 127 126 1
âãäåææ çèéêåë ìå
aths and illness
íîïðñõ óõñúöûôû
-0.0072 -0.0001 -- óõøøöúïò óõú÷ö÷úô 132 132 0
âãäåææ çèéêåë ìåaths and illness íîïðù óùñöúõõ -0.0003 0.0000 -- óùõöõñï óùôöúøò 116 116 0
âãäåææ çèéêåë ìå
aths and illness
íîïð÷ ó÷÷öôø÷
-0.0005 0.0000 -- ó÷ûöïòñ ó÷øöôùû 117 117 0
âãäåææ çèéêåë ìåaths and illness íîïðô óññôö÷õñ -0.0018 0.0000 -- óñ÷ùöôúï óñùøöøùû 121 121 0
âãäåææ çèéêåë ìå
aths and illness
íîïðõ óûòöòõô
-0.0014 0.0000 -- óñòôöù÷ù óñòñö÷ïï 120 120 0
âãäåææ çèéêåë ìåaths and illness íîïðï óñø÷ö÷÷ï -0.0029 -0.0001 -- óùñùöùúû óùòïöô÷û 123 123 0
âãäåææ çèéêåë ìå
aths and illness
íîïðú óùñøöõ÷ò
-0.0033 -0.0001 -- óùõùöùïû óùôõö÷÷û 124 124 0
âãäåææ çèéêåë ìåaths and illness íîïðø óñïõöôõô -0.0025 0.0000 -- óñûòöû÷ñ óñøõöïûù 122 122 0
âãäåææ çèéêåë ìå
aths and illness
íîïðû ó÷ô÷öòïï
-0.0051 -0.0001 -- ó÷ûõöûúû ó÷øõöñòõ 130 130 0
 ¡d smokiéü ýëåþåéêèßé PH14.1 ÷ñ÷öûùù 0.0057 0.0001
++
÷û÷öïøô ÷øòöùï÷ 24 25 -1
Child smoki
éü ýëåþåéêèßé
PH14.2
ùøöúûï
0.0005 0.0000
++
÷ïö÷úú ÷õöññï
49 49 0
C 
ó

ß

åëæ
PH15.10
ñúö÷ôûöï÷
0
0.3151 0.0052
++
ùñöïúõöûúô ùòöûïôöùôø
2 2 0
C 
ó

ß

åëæ
PH15.11
úöòñøö÷ú÷
0.1275 0.0021
++
øöúûòöòòñ øöôûôöïñû
3 3 0
C  ó ßåëæ PH15.13 õöïñùöøïò 0.1019 0.0017
++
úöòùûöûõõ ïöúû÷öñ÷ñ 7 7 0
C 
ó

ß

åëæ
PH15.15
÷öøôñöøòù
0.0699 0.0012
++
ôöøñúöñúõ ôöïõ÷öûûï
10 9 1
C  ó ßåëæ PH15.16 ùûõöòûñ 0.0054 0.0001
++
÷úñöñùø ÷õøö÷ûô 26 26 0
C 
ó

ß

åëæ
PH15.17
ùöùøïöúòù
0.0417 0.0007
++
ùöøúùöñùõ ùöúúôöùòõ
11 14 -3
C  ó ßåëæ PH15.20 ùöñôñöñûø 0.0389 0.0007
++
ùöïø÷öûïò ùöõûùöøôô 13 15 -2
C 
ó

ß

åëæ
PH15.21
ùò÷öúòõ
0.0037 0.0001
++
ùõõöôïø ùôïöúõú
29 29 0
C  ó ßåëæ PH15.22 õöõøúöøôô 0.1016 0.0017
++
úöòòñöñôú ïöúïõöòûõ 8 8 0
C 
ó

ß

åëæ ìèæìþéêüåì
PH15.24
ùøöñøò
0.0005 0.0000
++
÷õöõùù ÷ôöùûï
50 51 -1
C  ó ßåëæ ìèæìþéêüåì PH15.25 ñùöôøò 0.0013 0.0000
++
÷ôöòûù ÷ñöï÷û 57 46 11
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14
	
   ﬀ PH15.26 3ﬁﬂﬃﬂ 0.0386 0.0006
!!
99ﬁﬃ 33 9ﬂ"ﬃ#$3 23 22 1
	
   ﬀ
PH15.27
ﬂ"$ﬃ"ﬁ$
0.0276 0.0004
!!
ﬁ#ﬂﬃ#ﬂ ""#ﬃ
6
# 
25 24 1
	
   ﬀ PH15.28 #ﬃﬂﬂ3ﬃ"$6 0.1254 0.0019
!!
3ﬃﬂ3
6
ﬃ#"$ 3ﬃ  "ﬃ
6
9 17 11 6
	
   ﬀ
PH15.30
" ﬁﬃ
6
$
6 0.0633 0.0009
!!
#ﬃ"ﬂﬃ9
6
#ﬃ$#3ﬃ#
6
 
22 16 6
	
   ﬀ PH15.31 $ ﬃ#" 0.0052 0.0001
!!
#3
6
ﬃ3 #ﬂ$ﬃﬂ 9 42 32 10
	
   PH15.32
#9ﬃﬁﬁ
6
ﬃ#ﬁ
7
0.3592 0.0060
!!
ﬂ
6
ﬃ"9
6
ﬃ$ ﬂ3ﬃﬃ#3ﬁ 1 1 0
	
   ﬀ PH15.33 3"ﬃ9" 0.0007 0.0000
!!
6
"ﬃﬁ 
6
$ﬃﬂ3
6 44 45 -1
	
  
%

PH15.34
#$ﬁﬃ$$ 
0.0029 0.0000
!!
ﬂ  ﬃﬂ#" #93ﬃ#"
31 30 1
	
   PH15.37 ﬂﬃ#3$ﬃ ﬁﬂ 0.0878 0.0015
!!
ﬂﬃ3ﬂ3ﬃ"# ﬂﬃﬂﬁﬃ# # 14 18 -4
	
  
PH15.6
$ﬃ9$ﬃ#
0.1071 0.0018
!!
ﬁﬃ3$ﬃ
6
 ﬁﬃ#3"ﬃ""3
5 4 1
	
   PH15.8 $ﬃﬁ93ﬃ$9# 0.1053 0.0018
!!
ﬁﬃﬂ$ﬃ3" ﬁﬃ #3ﬃﬁ"
6 6 6 0
Physical activity in children PH17.1
#"9ﬃﬂ"ﬁ
-0.0009 0.0000
!&
#"3ﬃ"ﬂ3 #" ﬃﬁ""
30 36 -6
Physical activity in children PH17.2 "ﬃ6 # -0.0003 0.0000 -- 9ﬃ6ﬂ 9ﬃ##$ 112 112 0
Physical activity in children PH17.3
#ﬃ "ﬁ
0.0000 0.0000 -- #ﬃ33$ #ﬃﬂ93 102 103 -1
Physical activity in children PH17.4 6ﬃﬂ"ﬁ -0.0001 0.0000 -- $ﬃ#3 6ﬃ9ﬁ9 109 109 0
R

%'
 
bsenteeism PH19.1
ﬁﬂﬃﬁ3
0.0005 0.0000
!!
ﬁ9ﬃ$#3 ﬁﬁﬃ
6
9
6 39 41 -2
R%' bsenteeism PH19.2 3 ﬃﬂ"$ 0.0002 0.0000
!!
3ﬂﬃ"6# 3#ﬃﬂ" 48 53 -5
R

%'
 
bsenteeism PH19.3
ﬂ"#ﬃ
6
#$
0.0019 0.0000
!!
ﬂ
6
ﬃﬁﬁ ﬂﬁﬁﬃ"$ﬁ
27 28 -1
Eonal and social well(  'ondary schools PH20.1 ﬂﬃ$ 0.0000 0.0000
!&
ﬂﬃﬂ#9 ﬂﬃ#9ﬁ 66 74 -8
Immunisat

i

PH21.1 5 0.0000 0.0000
!!
6 5 85 88 -3
Immunisat i PH21.2 18 0.0000 0.0000
!!
20 19 81 86 -5

'
Sl(  n 
'

ssation PH23.1 6
ﬃ$ﬂ9
0.0001 0.0000
!!
ﬁﬃ
6
3# ﬁﬃ 
6
3
63 61 2
P   lcohol-use disorders PH24.2 ##ﬃ33 -0.0009 0.0000
!&
#ﬂ3ﬃ ﬂ3 ##9ﬃ 6ﬂ 35 38 -3

'

ssat
 n
i

)

PH26.1
#ﬃ9#ﬁ
0.0000 0.0000
!!
ﬂﬃ
6
3 ﬂﬃ3
6
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Physical acŁ   schemes PH54.8 -906 -0.0001 0.0000 --   100 104 -4
Key for Impact:  ncrease population health and reduce inequali  se population health and increase inequality;   ¡ ¢£¢¡ion health and reduce inequality; -- reduce 
population health and increase inequality
Notes¤ Positive cha¥ *M,  ¦§§  tes a reduction in absolute health inequality. Positive cha¥ £ ¨ ©ª£   «£¬ ­fare scores indicate an increase in social welfare® ¦haded 
rows indicate ¥¡  ­¨ ncreases in health inequality reduce social welfare to less than net population health be ®® ¯D¯°±²³
Page 38 of 38
http://mc.manuscriptcentral.com/mdm
Medical Decision Making
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
